Literature DB >> 20921316

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Thérèse Stachyra1, Marie-Claude Péchereau, Jean-Michel Bruneau, Monique Claudon, Jean-Marie Frère, Christine Miossec, Kenneth Coleman, Michael T Black.   

Abstract

NXL104 is a potent inhibitor of class A and C serine β-lactamases, including KPC carbapenemases. Native and NXL104-inhibited TEM-1 and P99 β-lactamases analyzed by liquid chromatography-electrospray ionization-time of flight mass spectrometry revealed that the inactivated enzymes formed a covalent adduct with NXL104. The principal inhibitory characteristics of NXL104 against TEM-1 and P99 β-lactamases were determined, including partition ratios, dissociation constants (K), rate constants for deactivation (k(2)), and reactivation rates. NXL104 is a potent inhibitor of TEM-1 and P99, characterized by high carbamylation efficiencies (k(2)/K of 3.7 × 10(5) M(-1) s(-1) for TEM-1 and 1 × 10(4) M(-1) s(-1) for P99) and slow decarbamylation. Complete loss of β-lactamase activity was obtained at a 1/1 enzyme/NXL104 ratio, with a k(3) value (rate constant for formation of product and free enzyme) close to zero for TEM-1 and P99. Fifty percent inhibitory concentrations (IC(50)s) were evaluated on selected β-lactamases, and NXL104 was shown to be a very potent inhibitor of class A and C β-lactamases. IC(50)s obtained with NXL104 (from 3 nM to 170 nM) were globally comparable on the β-lactamases CTX-M-15 and SHV-4 with those obtained with the comparators (clavulanate, tazobactam, and sulbactam) but were far lower on TEM-1, KPC-2, P99, and AmpC than those of the comparators. In-depth studies on TEM-1 and P99 demonstrated that NXL104 had a comparable or better affinity and inactivation rate than clavulanate and tazobactam and in all cases an improved stability of the covalent enzyme/inhibitor complex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921316      PMCID: PMC2981269          DOI: 10.1128/AAC.00568-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Beta-lactamase TEM1 of E. coli. Crystal structure determination at 2.5 A resolution.

Authors:  C Jelsch; F Lenfant; J M Masson; J P Samama
Journal:  FEBS Lett       Date:  1992-03-09       Impact factor: 4.124

2.  Automated analysis of enzyme inactivation phenomena. Application to beta-lactamases and DD-peptidases.

Authors:  F De Meester; B Joris; G Reckinger; C Bellefroid-Bourguignon; J M Frère; S G Waley
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

3.  Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.

Authors:  K Bush; C Macalintal; B A Rasmussen; V J Lee; Y Yang
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  Crystallographic data for the beta-lactamase from Enterobacter cloacae P99.

Authors:  P Charlier; O Dideberg; J M Frère; P C Moews; J R Knox
Journal:  J Mol Biol       Date:  1983-12-05       Impact factor: 5.469

5.  Interaction of clavulanate with the beta-lactamases of Streptomyces albus G and Actinomadura R39.

Authors:  J M Frère; C Dormans; V M Lenzini; C Duyckaerts
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

6.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

7.  Partial amino acid sequence of penicillinase coded by Escherichia coli plasmid R6K.

Authors:  R P Ambler; G K Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

8.  Evidence that the catalytic activity of prokaryote leader peptidase depends upon the operation of a serine-lysine catalytic dyad.

Authors:  M T Black
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

9.  Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution.

Authors:  N C Strynadka; H Adachi; S E Jensen; K Johns; A Sielecki; C Betzel; K Sutoh; M N James
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

10.  Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose.

Authors:  S J Cartwright; S G Waley
Journal:  Biochem J       Date:  1984-07-15       Impact factor: 3.857

View more
  54 in total

1.  Kinetics of the Interaction between BAL29880 and LK157 and the Class C β-Lactamase CHE-1.

Authors:  Adriana Fernea; Moreno Galleni; Jean-Marie Frère
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

2.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors:  A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

4.  Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Authors:  David E Ehmann; Haris Jahic; Philip L Ross; Rong-Fang Gu; Jun Hu; Thomas F Durand-Réville; Sushmita Lahiri; Jason Thresher; Stephania Livchak; Ning Gao; Tiffany Palmer; Grant K Walkup; Stewart L Fisher
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

Review 5.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

7.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

8.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.

Authors:  Gregory G Stone; Patricia A Bradford; Margaret Tawadrous; Dianna Taylor; Mary Jane Cadatal; Zhangjing Chen; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

10.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.